naloxone - Page 1 | CARLAT PUBLISHING

Expert Q&A

Addressing the Overdose Crisis: What You Can Do

January 1, 2025

Aaron Quiggle, MD, MS

Adult, child, and adolescent addiction psychiatrist; Medical Director, Addiction Recovery Management Service (ARMS), Massachusetts General Hospital, Boston, MA.

Dr. Quiggle is a co-investigator of an investigator-sponsored trial for Ironshore Pharmaceuticals. Relevant financial relationships have been mitigated.

There are multiple ways that we can help our patients reduce the risk of overdose. In our interview with Dr. Aaron Quiggle, we cover screening, fentanyl testing, the use of Narcan and the importance of learning to prescribe buprenorphine.

Clinical Update

Post X-Waiver Buprenorphine Prescribing

September 26, 2024

Noah Capurso, MD

Noah Capurso, MD, MHS. Associate Professor of Psychiatry, Yale University, New Haven, CT; Editor-in-Chief, The Carlat Addiction Treatment Report.

Dr. Capurso has no financial relationships with companies related to this material.

All clinicians need to know how to use buprenorphine under the DEAs new regulations. Meanwhile, the fentanyl crisis is changing how we use it. Noah Capurso shows us how to navigate these waters.

Note From the Editor-in-Chief

July 1, 2024

Joshua D. Feder, MD.

Dr. Feder remains alarmed: right now, it’s about heat, social media, and fentanyl - hear his direct advice and protect your patients and yourselves from the current ravages of our times.

Research Update

Methamphetamines and Opioid-Related Overdose Risk

April 1, 2023

Peter J. Farago, MD.

Peter J. Farago, MD. Dr. Farago has no financial relationships with companies related to this material.

Researchers provide a detailed glimpse into the chaotic state of the illicit opioid supply and show that the potentially dangerous misconception that methamphetamines can be used as an opioid overdose reversal agent is widespread.

Drug Overdoses in the US: Trends and Prevention Strategies

November 5, 2021

Joshua Sharfstein, MD

Joshua Sharfstein, MD

Professor of the Practice of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.

Dr. Sharfstein has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Increases in drug overdose mortality continues unabated around the country driven by widespread availability of illicit fentanyl and methamphetamines. Dr. Sharfstein provides context to these concerning trends and discusses prevention and harm reduction strategies clinicians can implement for their patients.

Naloxone Prescribing

July 3, 2021

Phillip Coffin, MD

Phillip Coffin, MD
Director of Substance Use Research, San Francisco Department of Public Health, San Francisco, CA. Dr. Coffin has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Dr. Coffin provides our readers with everything there is to know about the nuts and bolts of naloxone prescribing for opioid use disorder. He tells us how patients can get their hands on naloxone, reviews the pros, cons, and costs of various naloxone formulations, and covers current naloxone laws.

A New High-Dose Naloxone: Life Saver or Punishment?

July 3, 2021

Noah Capurso, MD

Noah Capurso, MD

Dr. Capurso has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

The FDA recently approved a nasal spray formulation of naloxone. Called Kloxxado, each spray delivers 8mg, twice as much as the most widely used formulation, Narcan. Whether or not this higher dose is necessary, is debatable.

New Generic Versions of Naloxone

August 1, 2019

Talia Puzantian, PharmD, BCPP.

Talia Puzantian, PharmD, BCPP. Dr. Puzantian has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Naloxone, a rescue medication effective for reversing opioid overdose, will soon be available in two generic forms for layperson use. This news of note summarizes these generic, lower-cost products.